Source reading · a16z Big Ideas 2026
Forty-seven contributions offer many views of what might come next. The useful founder question is smaller: which task could be tested now, and what result would change the decision to build?
This reading covers the three original parts published on 9, 10 and 11 December 2025. The collection mixes forecasts, proposed products, company illustrations and strategy or policy arguments. A prediction about 2026 remains a dated prediction; it is not silently updated into an observed fact.
A cleaner input is useful when the next decision changes correctly. Track one stale document, conflicting definition or failed handoff from discovery through correction to the person using the result. If an error survives in a downstream copy, the workflow is still broken. This makes a more concrete investigation than starting with an ambition to replace an entire stack.
A call, a delegated task and a service request each cross a boundary between people or systems. Name what was requested, who authorised it, what changed and who accepts the result. Then rehearse a partial failure. A clear receipt or recovery process may be more useful than increasing the amount of work an agent attempts autonomously.
A promising result should survive a test the product does not get to choose after seeing the answer. That might be unassisted learner performance, a researcher reproducing a derivation, an operator explaining a rejected action or a creator returning to continue a project. Include correction and review effort. More outputs, more engagement or agreement between models can hide a worse outcome.
A distribution channel, a data supplier or a proposed settlement arrangement may be essential to a product. Write down what happens if that dependency changes, refuses a request or cannot recover an error. The investigation can reveal a useful integration, a service with substantial operating work or a plan that depends on permission or evidence it does not yet have.
A workflow investigation travels more easily than its surrounding market premise. Ask a specific Indian operator which records they use, who may change them, how work reaches another party and what an error costs. For a proposed voice service, test the real participants’ languages and escalation needs. For an industrial workflow, inspect an actual site’s equipment, maintenance and acceptance process. These are local research questions, not assumed Indian advantages.
American Dynamism is explicitly a US industrial perspective. The health and financial contributions also carry payer, institutional or jurisdictional assumptions that should not be imported into India. Crypto architecture does not by itself establish an operating permission. The legal-policy contribution remains conditional and US-specific; this reading does not report a current legislative status or recommend a financial, clinical or investment product.
Each titled contribution remains one occurrence even when it mentions several technologies or existing companies. The company examples illustrate the contributor’s argument; they are not independently validated businesses or additional requests to copy. Similar ideas across parts remain visible without being counted as demand evidence.
Fourteen contributions. Investigate the information, control or learning result the proposed product would change.
Published 9 December 2025 · 14 contributions
Sixteen contributions. Keep US industrial strategy separate from portable workflow experiments.
Published 10 December 2025 · 16 contributions
Seventeen contributions. Separate technical proposals, financial-product assumptions and a conditional US legal forecast.
Published 11 December 2025 · 17 contributions
Thirty-eight entries have compact investigation notes. Nine remain source-only: persistent interactive video, recurring preventive health, broad personalisation, the industrial-base umbrella, the electro-industrial stack, the new-model-primitives umbrella, crypto trading strategy, tokenised wealth management and the conditional US legal-architecture forecast. Their source context is visible, but this review does not manufacture technical readiness, clinical or financial outcomes, a first buyer or legal permission from it.
The investigations above are Bharat in Beta’s editorial hypotheses. Source images, article bodies and performance, market-size or adoption figures are not reproduced. A successful small experiment would still need its own commercial and domain review before becoming a product.
Bharat in Beta